All In Biotech

Free tool

FAERS Monitor: Stalevo 75

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021485 or its brand name (Stalevo 75, Carbidopa, Entacapone, Levodopa). Reports on generic versions are filed under their own applications.

Reports

481

Serious

355

74% of reports

Hospitalization

194

Death reported

88

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fall69
  • death54
  • hallucination52
  • drug ineffective43
  • parkinson^s disease41
  • dyskinesia27
  • urinary tract infection27
  • product dose omission issue25
  • confusional state24
  • device issue21
  • fatigue18
  • somnolence18
  • asthenia17
  • gait disturbance17
  • insomnia17

Reports by year received

View as table
YearReports
20113
20121
20133
20144
20153
20169
201734
201842
201938
202061
202157
202264
202360
202446
202556

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,678 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
hallucinationSignal5230.223.41,443
dyskinesiaSignal2729.120.1705
device issueSignal2110.26.7167
fallSignal699.17.3495
urinary tract infectionSignal276.94.8132
confusional stateSignal246.54.4107
somnolenceSignal183.92.536
gait disturbanceSignal173.92.434
product dose omission issueSignal253.72.548
insomniaSignal172.81.718
deathSignal542.72.160
asthenia172.01.27
drug ineffective431.41.15
fatigue181.00.60
parkinson^s disease410.00.01,751,095

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.